Does LORLATINIB Cause Interstitial lung disease? 23 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Interstitial lung disease have been filed in association with LORLATINIB (Lorbrena). This represents 0.4% of all adverse event reports for LORLATINIB.
23
Reports of Interstitial lung disease with LORLATINIB
0.4%
of all LORLATINIB reports
4
Deaths
11
Hospitalizations
How Dangerous Is Interstitial lung disease From LORLATINIB?
Of the 23 reports, 4 (17.4%) resulted in death, 11 (47.8%) required hospitalization, and 3 (13.0%) were considered life-threatening.
Is Interstitial lung disease Listed in the Official Label?
Yes, Interstitial lung disease is listed as a known adverse reaction in the official FDA drug label for LORLATINIB.
What Other Side Effects Does LORLATINIB Cause?
Death (1,050)
Neoplasm progression (633)
Off label use (394)
Weight increased (306)
Hallucination (290)
Blood cholesterol increased (281)
Dyspnoea (223)
Oedema peripheral (198)
Oedema (195)
Fatigue (188)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which LORLATINIB Alternatives Have Lower Interstitial lung disease Risk?
LORLATINIB vs LORMETAZEPAM
LORLATINIB vs LORNOXICAM
LORLATINIB vs LOSARTAN
LORLATINIB vs LOSARTAN\LOSARTAN
LORLATINIB vs LOTEPREDNOL ETABONATE